title: Daily compared with 8-hour gentamicin for the treatment of intrapartum chorioamnionitis: a randomized controlled trial.
abstract: OBJECTIVE
  To assess whether daily gentamicin is as effective as 8-hour gentamicin for the treatment of intrapartum chorioamnionitis.
  
  
  METHODS
  Women with a clinical diagnosis of chorioamnionitis between 32 and 42 weeks of gestation were randomly assigned in labor to receive either daily gentamicin (5 mg/kg intravenously (IV), then 2 placebo doses IV after 8 and 16 hours) or 8-hour gentamicin (2 mg/kg IV, then 1.5 mg/kg IV after 8 and 16 hours). Both groups received ampicillin (2 grams IV every 6 hours for a total of four doses). Patients who underwent cesarean delivery also received clindamycin (900 mg IV every 8 hours, for a total of three doses). The primary outcome was treatment success, defined by resolution of chorioamnionitis after 16 hours of treatment without development of endometritis. One hundred twenty-six patients were required to have 95% confidence that daily gentamicin is at worst 15% inferior to 8-hour dosing with an alpha of .05 and a beta of 0.2.
  
  
  RESULTS
  One hundred twenty-six women were enrolled, of whom 63 received daily gentamicin and 63 received 8-hour gentamicin. One patient was excluded from data analysis. Baseline maternal and obstetric characteristics were similar between groups except for longer mean duration of ruptured membranes in the 8-hour group (679+/-514 compared with 469+/-319 minutes; P =.03). Treatment success was equal between groups (94% daily gentamicin compared with 89% 8-hour gentamicin, P =.53). There were no differences in maternal or neonatal morbidities, including neonatal sepsis and newborn hearing screen.
  
  
  CONCLUSIONS
  Daily and 8-hour gentamicin appear equally effective for the treatment of intrapartum chorioamnionitis.
  
  
  BACKGROUND
  ClinicalTrials.gov, www.clinicaltrials.gov, NCT00185991.
  
  
  METHODS
  I.
authors.affiliation: From the Department of Obstetrics and Gynecology, Lucile S. Packard Children's Hospital at Stanford, Stanford, California; Department of Obstetrics and Gynecology, University of California San Francisco, San Francisco, California; and Department of Pediatrics, Lucile S. Packard Children's Hospital at Stanford, Stanford, California.
authors.forename: Deirdre J
authors.initials: DJ
authors.lastname: Lyell
authors.forename: Kristin
authors.initials: K
authors.lastname: Pullen
authors.forename: Katherine
authors.initials: K
authors.lastname: Fuh
authors.forename: A Musa
authors.initials: AM
authors.lastname: Zamah
authors.forename: Aaron B
authors.initials: AB
authors.lastname: Caughey
authors.forename: William
authors.initials: W
authors.lastname: Benitz
authors.forename: Yasser Y
authors.initials: YY
authors.lastname: El-Sayed
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002821:Chorioamnionitis / Q000188:drug therapy*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005322:Premature Rupture of Fetal Membranes; D005839:Gentamicins / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D011247:Pregnancy; D011263:Pregnancy Trimester, Third
chemical_list: D000900:Anti-Bacterial Agents; D005839:Gentamicins